Department of Pediatric Nephrology, Emma Children's Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands
Department of Pediatric Nephrology, Emma Children's Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Pediatrics. 2021 Jul;148(1). doi: 10.1542/peds.2020-029249. Epub 2021 Jun 30.
Idiopathic nephrotic syndrome (INS) in children is a disease with considerable morbidity, yet the incidence and risk for relapse have not been systematically reviewed.
To estimate the overall pooled weighted incidence and risk for relapse of INS in children.
Medline and Embase (until December 2020).
All studies reporting incidence (per 100 000 children per year) and/or risk for relapse (the proportion of patients who experience ≥1 relapse) of INS in children (age: <18 years) were eligible.
After quality assessment, data were extracted: study (design, localization, and sample size) and patient (age, sex, steroid response, and ethnicity) characteristics, incidence, and risk for relapse.
After screening, 73 studies were included for analysis (27 incidence, 54 relapse). The overall pooled weighted estimate and corresponding prediction interval (PI) of the incidence was 2.92 (95% PI: 0.00-6.51) per 100 000 children per year. Higher incidences were found in non-Western countries ( < .001). Incidence tended to be lower in white children, but this was not significant. The overall pooled weighted estimate of the risk for relapse was 71.9% (95% PI: 38.8-95.5). Between 1945 and 2011, incidence did not change ( = .39), yet the risk for relapse decreased significantly ( = .024), from 87.4% to 66.2%.
There was no full-text availability ( = 33), considerable heterogeneity, and limited studies from Africa, Latin America, and Asia.
INS has a low incidence with ethnic variation but high risk for relapse. Although corticosteroids have significantly reduced the risk for relapse, it remains unacceptably high, underscoring the need for alternative treatment strategies.
儿童特发性肾病综合征(INS)是一种发病率较高的疾病,但目前尚未对其发病率和复发风险进行系统评估。
评估儿童特发性肾病综合征的总体累积加权发病率和复发风险。
Medline 和 Embase(截至 2020 年 12 月)。
所有报告儿童(年龄<18 岁)INS 发病率(每 10 万名儿童/年)和/或复发风险(经历≥1 次复发的患者比例)的研究均符合入选标准。
经过质量评估后,提取研究(设计、定位和样本量)和患者(年龄、性别、激素反应和种族)特征、发病率和复发风险等数据。
经过筛选,共有 73 项研究纳入分析(27 项发病率研究,54 项复发风险研究)。发病率的总体累积加权估计值及其相应预测区间(PI)为 2.92(95%PI:0.00-6.51)/10 万名儿童/年。非西方国家的发病率较高(<.001)。白人儿童的发病率较低,但差异无统计学意义。复发风险的总体累积加权估计值为 71.9%(95%PI:38.8-95.5)。1945 年至 2011 年期间,发病率没有变化( =.39),但复发风险显著降低( =.024),从 87.4%降至 66.2%。
有 33 项研究无法获取全文,存在较大异质性,且来自非洲、拉丁美洲和亚洲的研究较少。
INS 的发病率较低,存在种族差异,但复发风险较高。尽管皮质激素显著降低了复发风险,但仍居高不下,这突显了需要替代治疗策略的必要性。